首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Therapeutic Advances In Hematology

Therapeutic Advances In Hematology杂志,由SAGE PUBLICATIONS LTD出版,于2010年创刊,1 issue/year,出版语言English,ISSN:2040-6207,E-ISSN:2040-6215。

投稿咨询
Therapeutic Advances In Hematology
Therapeutic Advances In Hematology
Therapeutic Advances In Hematology
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
2区
影响因子
2.8
CiteScore
5.3
期刊收录
SCI、SCIE

Therapeutic Advances In Hematology(中文译名:《血液学的治疗进展》),ISSN:2040-6207,EISSN:2040-6215,是SAGE PUBLICATIONS LTD出版的国际性学术期刊,创刊于2010年,以1 issue/year形式稳定发行,2026年总发文量约58篇。该刊采用OA开放访问,学科归属为HEMATOLOGY。该刊是医学、血液学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达2.8,2025年期刊CiteScore为5.3,2025年期刊自引率约3.6%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Therapeutic Advances In Hematology长期聚焦医学、血液学及相关产业的技术应用前沿,平均审稿周期7 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、血液学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAItaly、CHINA MAINLAND、England、France、South Korea、Spain等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMMAYO CLINIC、HARVARD UNIVERSITY、ASSISTANCE PUBLIQUE HOPITAUX PARIS (APHP)、CHINESE ACADEMY OF MEDICAL SCIENCES - PEKING UNION MEDICAL COLLEGE、DANA-FARBER CANCER INSTITUTE、SEOUL ST. MARY'S HOSPITAL等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
HEMATOLOGY 血液学
2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
HEMATOLOGY 血液学
3区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
HEMATOLOGY 血液学
3区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q2 42 / 103

59.7

学科:HEMATOLOGY SCIE Q2 42 / 103

59.71

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q2 28 / 97

71.6

学科:HEMATOLOGY SCIE Q2 39 / 97

60.31


中国学者近期发文

1
A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysi

Author:Sawa, Masashi; Miyamoto, Toshihiro; Kim, Hee-Je; Hiramatsu, Yasushi; Cheong, June-Won; Ikezoe, Takayuki; Naoe, Tomoki; Akashi, Koichi; Morita, Satoshi; Kosako, Masanori; Shimura, Masaki; Terada, Wataru; Kadokura, Takeshi; Hill, Jason; Miyawaki, Shuichi; Gill, Stanley C.; Heinloth, Alexandra; Hasabou, Nahla

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261419953

2
Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB tria

Author:Yang, Linyu; Tan, Ke; Liang, Rui; Zhang, Wei; Wang, Yiqun; Chen, Lijuan

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261424845

3
The impact of clinical manifestations on the prognosis of diffuse large B-cell lymphom

Author:Wang, Siqian; Xu, Xi; Ma, Yongyong; Qian, Shanhu; Tang, Liyuan; Sun, Lan; Shen, Zhijian; Ye, Haige; Qian, Honglan; Jiang, Songfu; Zhou, Shujuan

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207251410405

4
Early-onset de novo donor-specific anti-HLA antibodies may contribute to poor graft function following haploidentical transplantation for myelodysplastic syndrome: a rare case presentatio

Author:Huang, Xianbo; Wu, Xianhui; Wang, Shasha; Xu, Yu; Mei, Chen; Du, Fengwei; Ren, Yanling; Jin, Jie; Tong, Hongyan; Qian, Jiejing

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417496

5
Real-world clinical outcomes of autologous stem cell transplantation in Chinese patients with newly diagnosed multiple myeloma: a systematic literature revie

Author:You, Jiawen; Zhang, Yuanyuan; Meng, Yuan; Zhao, Yiming; Huang, Huiqing; Chen, Wendong; Meng, Jianbo

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417132

6
Endothelial dysfunction and cardiac damage indicators in patients with β-thalassemia major under iron-chelation therap

Author:Al-Sanabra, Ola M.; Abbas, Manal A.; Haza, Wafa J.; Hazaa, Abeer A

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417140

7
Comparing two different doses of anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent thalassemia: an open-label, randomized clinical tria

Author:Huang, Qiulin; Liu, Rongrong; Zheng, Baoshi; Liu, Lianjin; Xiao, Hongwen; Wu, Meiqing; Shi, Lingling; Yang, Gaohui; Wei, Zhenbin; Zhou, Qi; Chen, Yinghua; Liu, Yanye; Fan, Jing; Zhou, Xuemei; Li, Ruolin; Zeng, Zhiyu; Zhang, Zhongming; Lai, Yongrong

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261416816

8
Recombinant von Willebrand factor for von Willebrand disease: mechanism of action and clinical applicatio

Author:Hua, Zhengjie; Miao, Wenjuan; Zhang, Ping; Yang, Renchi

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261419941

9
Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysi

Author:Li, Qiang; Xu, Shenghua; Zhong, Yun; Rao, Peng; Huang, Hui; Huang, Yan

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207251407511

10
The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: a systematic review and meta-analysi

Author:Fan, Zixin; Xie, Jiayi; Su, Pinying; Tai, Jingye; Feng, Weiyi; Xu, Rui; Ouyang, Yun

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2025; Vol. 16, Issue , pp. -. DOI: 10.1177/20406207251342203


在线咨询

Therapeutic Advances In Hematology

国际简称:THER ADV HEMATOL参考译名:血液学的治疗进展

年发文量:58 CiteScore:5.3 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:84.48%

杂志社联系方式:1 OLIVERS YARD, 55 CITY ROAD, LONDON, ENGLAND, EC1Y 1SP

Therapeutic Advances In Hematology